ES8704515A1 - Procedimiento para preparar interferones alfa, beta y omega de equino o interferon alfa de canino - Google Patents

Procedimiento para preparar interferones alfa, beta y omega de equino o interferon alfa de canino

Info

Publication number
ES8704515A1
ES8704515A1 ES550043A ES550043A ES8704515A1 ES 8704515 A1 ES8704515 A1 ES 8704515A1 ES 550043 A ES550043 A ES 550043A ES 550043 A ES550043 A ES 550043A ES 8704515 A1 ES8704515 A1 ES 8704515A1
Authority
ES
Spain
Prior art keywords
canine
interferons
interferon
equine
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES550043A
Other languages
English (en)
Spanish (es)
Other versions
ES550043A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of ES550043A0 publication Critical patent/ES550043A0/es
Publication of ES8704515A1 publication Critical patent/ES8704515A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ES550043A 1984-12-18 1985-12-17 Procedimiento para preparar interferones alfa, beta y omega de equino o interferon alfa de canino Expired ES8704515A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3446122 1984-12-18
DE3446124 1984-12-18
DE3529262 1985-08-16
DE3535115 1985-10-02

Publications (2)

Publication Number Publication Date
ES550043A0 ES550043A0 (es) 1987-04-01
ES8704515A1 true ES8704515A1 (es) 1987-04-01

Family

ID=27433247

Family Applications (1)

Application Number Title Priority Date Filing Date
ES550043A Expired ES8704515A1 (es) 1984-12-18 1985-12-17 Procedimiento para preparar interferones alfa, beta y omega de equino o interferon alfa de canino

Country Status (19)

Country Link
US (2) US5605688A (enExample)
EP (1) EP0186098B1 (enExample)
JP (1) JPH0753596A (enExample)
KR (1) KR940010864B1 (enExample)
AT (1) ATE77410T1 (enExample)
AU (1) AU604634B2 (enExample)
CA (1) CA1339954C (enExample)
DE (1) DE3544520C2 (enExample)
DK (1) DK167929B1 (enExample)
ES (1) ES8704515A1 (enExample)
FI (1) FI90990C (enExample)
GR (1) GR853062B (enExample)
HU (1) HU212836B (enExample)
IE (1) IE58685B1 (enExample)
IL (1) IL77369A (enExample)
NO (1) NO176057C (enExample)
NZ (1) NZ214602A (enExample)
PT (1) PT81691B (enExample)
WO (1) WO1986003775A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
DE3932311A1 (de) * 1989-09-28 1991-04-11 Boehringer Ingelheim Int Verfahren zur reinigung von beta-interferon
US20020127200A1 (en) 1998-05-29 2002-09-12 Shumin Yang Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
USRE40374E1 (en) 1998-05-29 2008-06-10 Heska Corporation Canine IL-13 immunoregulatory proteins and uses thereof
AU4102099A (en) 1998-05-29 1999-12-13 Heska Corporation Canine Interleukin -4 Proteins, Nucleic Acid Molecules, and Uses Thereof
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
CN101062419B (zh) 1998-10-16 2016-06-29 生物基因Ma公司 干扰素-β-1a的聚合物缀合物及其使用
CN100420482C (zh) * 2000-11-03 2008-09-24 精达制药公司 ω干扰素在制备用于治疗丙型肝炎的药物中的用途
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
HRP20180621T1 (hr) 2011-03-15 2018-07-27 Biogen Ma Inc. Postupak smanjivanja simptoma sličnih gripi, povezan s intramuskularnom primjenom interferona uz upotrebu režima rastuće doze uz brzo titranje
CN102321169A (zh) * 2011-09-30 2012-01-18 长春工业大学 一种犬重组干扰素α及制备方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CN108424915A (zh) * 2018-01-12 2018-08-21 中国农业科学院北京畜牧兽医研究所 犬干扰素-α2重组蛋白的制备方法
CN108486127A (zh) * 2018-01-12 2018-09-04 中国农业科学院北京畜牧兽医研究所 犬干扰素-α6α7重组蛋白及其制备方法与应用
CN111233998B (zh) * 2018-08-02 2021-10-19 中国农业科学院北京畜牧兽医研究所 一种犬干扰素CaIFN-λ突变体及其应用
GB202011945D0 (en) * 2020-07-31 2020-09-16 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases
CN112079912B (zh) * 2020-09-25 2022-05-06 广州源博医药科技有限公司 一种高活性的犬α干扰素重组蛋白及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980002375A1 (en) * 1977-09-23 1980-11-13 Hem Res Inc High purity animal interferons
US4262090A (en) * 1979-06-04 1981-04-14 Cetus Corporation Interferon production
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
ATE25985T1 (de) * 1980-06-12 1987-04-15 Japan Found Cancer Plasmid.
US4436815A (en) * 1981-11-27 1984-03-13 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cells
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
AR241654A1 (es) * 1982-05-05 1992-10-30 Genentech Inc Procedimiento para producir activador de plasminogeno de tejido humano.
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
JPS60118196A (ja) * 1983-11-30 1985-06-25 Takeda Chem Ind Ltd インタ−フェロンの製造法
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
US4689224A (en) * 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor

Also Published As

Publication number Publication date
WO1986003775A1 (fr) 1986-07-03
NO176057C (no) 1995-01-25
NO176057B (no) 1994-10-17
EP0186098A1 (de) 1986-07-02
DK167929B1 (da) 1994-01-03
ES550043A0 (es) 1987-04-01
FI854994L (fi) 1986-06-19
FI90990B (fi) 1994-01-14
ATE77410T1 (de) 1992-07-15
AU5132085A (en) 1986-06-26
NZ214602A (en) 1991-06-25
NO855078L (no) 1986-06-19
AU604634B2 (en) 1991-01-03
PT81691A (de) 1986-01-01
GR853062B (enExample) 1986-04-21
JPH0753596A (ja) 1995-02-28
US5605688A (en) 1997-02-25
DK586585A (da) 1986-06-19
FI854994A0 (fi) 1985-12-16
DE3544520C2 (de) 1995-07-20
DE3544520A1 (de) 1986-12-18
FI90990C (fi) 1994-04-25
KR940010864B1 (ko) 1994-11-18
KR860005020A (ko) 1986-07-16
IE58685B1 (en) 1994-02-09
CA1339954C (en) 1998-07-14
IL77369A (en) 1993-07-08
HU212836B (en) 1996-12-30
HUT40165A (en) 1986-11-28
EP0186098B1 (de) 1992-06-17
DK586585D0 (da) 1985-12-17
US5798228A (en) 1998-08-25
PT81691B (pt) 1988-04-21
IE853194L (en) 1986-06-18

Similar Documents

Publication Publication Date Title
ES8704515A1 (es) Procedimiento para preparar interferones alfa, beta y omega de equino o interferon alfa de canino
ES557100A0 (es) Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped
DE3650538D1 (de) Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
AR241654A1 (es) Procedimiento para producir activador de plasminogeno de tejido humano.
BR9814568A (pt) "inseminação sexual especìfica de mamìferos com baixo número de células espermatozóides"
ATE125869T1 (de) Wachstumshormonfusionsproteine.
DK111183D0 (da) Polypeptid omfattende aminosyresekvensen af et dyreinterferon, dna-sekvens, der koder for polypeptidet, replicerbart udtrykkelsesmedium, som kan udtrykke dna-sekvensen, og fremgangsmade til fremstilling af polypeptidet
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
ES499262A0 (es) Procedimiento para la obtencion de un microorganismo que forma un polipetido con la secuencia de aminoacidos del inter- feron de leucocitos humanos.
ES8800266A1 (es) Un metodo para obtener un polipeptido complementario de al menos una porcion de un peptido o proteina original
NO902393L (no) Dna som koder for ige-reseptor alfa-underenhet eller fragment derav.
DK308586A (da) Dna-sekvens, der koder for et specifikt protein, rekombinantvektor, der omfatter sekvensen, og celler, der er transficerede til ekspression af proteinet
DK127786D0 (da) Fremgangsmaade til fremstilling af tgf-beta, dna og mrna, som koder for tgf-beta, samt replicerbare vektorer omfattende dna'en og vaertscellerindeholdende vektorerne
ES2174530T3 (es) Complejo ifnar/ifn.
ES2062982T3 (es) Clonaje y expresion del factor de crecimiento de fibroblasto acido.
ATE285416T1 (de) Expression und reinigung von kloniertem humanen alpha-fetoprotein
ES2058053T5 (es) Interferon beta2a humano; vectores que contienen genes codantes para el indicado interferon, lineas de celulas que lo producen y utilizacion de dicho interferon a titulo de medicamento.
DE3850774D1 (de) Rinder-interleukin-1-alpha.
DE3852777D1 (de) Verfahren zur Konstruktion einer animalen Zellinie für die Herstellung von humanem Interferon-beta.
RU2004106774A (ru) Белок ifnab-bpi, его предшественник, молекула днк, экспрессирующий вектор, способ продуцирования, фармацевтическая композиция для ингибирования активности ifn-альфа или ifn-бета
ES8607392A1 (es) Un procedimiento para producir un polipeptido que exhibe ac-tividad de factor de fijacion de ige de mamifero
ATA435083A (de) Das polypeptid interleukin-2 kodierendes gen, rekombinante, dieses gen enthaltende dna, diese rekombinante dna aufweisende zellinien und verfahren zur herstellung von interleukin-2 unter verwendung der genannten zellen
ES2054608T3 (es) Un metodo para la expresion de genes en levadura y fragmentos de adn asi como plasmidos que comprenden dichos fragmentos de adn para uso cuando se lleva a cabo dicho metodo.
AR242636A1 (es) Gen con codificacion para actividad de factor estimulante de colonias de granulocitos humanos.
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20040916